Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T40051 |
Acid Ceramidase-IN-1
|
||
Acid Ceramidase-IN-1 is a highly effective and orally bioavailable inhibitor of acid ceramidase (AC, ASAH-1), with an inhibitory concentration (IC50) of 0.166 μM. Additionally, Acid Ceramidase-IN-1 exhibits exceptional brain penetration capabilities in mice. | |||
T75142 | Acid Ceramidase-IN-2 | ||
Acid Ceramidase-IN-2(compound 1)是一款针对酸性神经酰胺酶(ceramidase)的抑制剂,显示出抗增殖及细胞活性抑制的潜力。有研究表明,该化合物在前列腺癌细胞中可阻止人酸性神经酰胺酶的过度表达,从而揭示了其潜在的抗肿瘤能力。此外,Acid Ceramidase-IN-2被三种α-酮酰胺:GT85、GT98和GT99在体外有效抑制其水解作用。 | |||
T21658 |
ARN14974
|
Others | Others |
ARN14974 是一种有效的全身活性的胞内酸性神经酰胺酶抑制剂 (IC50=79 nM),是一种苯并恶唑酮甲酰胺化合物。 | |||
T75406 | Endoglycoceramidase II (EGCase II) | ||
Endoglycoceramidase II (EGCase II) 是一种能从糖鞘脂的神经酰胺部分释放完整聚糖的内切-β-葡萄糖苷酶。该酶专门催化多种糖鞘脂中寡糖与神经酰胺之间的 β-糖苷键的水解反应。 | |||
T75407 | Endoglycoceramidase I (EGCase I) | ||
Endoglycoceramidase I (EGCase I)为糖苷酶,广泛应用于生化研究。该酶具有催化转糖基化反应的功能,能将GSL的糖组分高效转移至多种1-烷醇的伯羟基。 | |||
T10762 |
Ceranib1
|
Others | Others |
Ceranib1 是一种神经酰胺酶 (ceramidase) 抑制剂, 能抑制细胞神经酰胺酶对外源性神经酰胺类似物的活性,诱导多种神经酰胺物质的积累,降低鞘氨醇和 S1P 水平。Ceranib1 能抑制细胞卵巢癌细胞增殖。 | |||
T10761 |
Ceranib-2
3-[(E)-3-(4-hydroxyphenyl)prop-2-enoyl]-4-phenyl-1H-quinolin-2-one |
Apoptosis; S1P Receptor | Apoptosis; GPCR/G Protein |
Ceranib-2 (3-[(E)-3-(4-hydroxyphenyl)prop-2-enoyl]-4-phenyl-1H-quinolin-2-one) 是一种神经酰胺酶抑制剂,在 SKOV3 细胞中的 IC50 为 28 μM。 Ceranib-2 降低鞘氨醇和 S1P 的水平,诱导细胞凋亡并表现出抗癌活性。 | |||
T1307 |
Carmofur
HCFU,卡莫氟 |
Nucleoside Antimetabolite/Analog; Virus Protease; SARS-CoV; DNA/RNA Synthesis | Cell Cycle/Checkpoint; DNA Damage/DNA Repair; Microbiology/Virology |
Carmofur (HCFU) 是 5-氟尿嘧啶的衍生物,是一种抗肿瘤药物。它是一种酸性神经酰胺酶抑制剂,用于治疗乳腺癌和结直肠癌。它抑制 SARS-CoV-2主要蛋白酶,还抑制 Vero E6 细胞 SARS-CoV-2,EC50为 24.3 μM。 | |||
T40542 |
Sinbaglustat
ACT-519276,Sinbaglustat,OGT2378 |
Transferase | Metabolism |
Sinbaglustat (OGT2378) (OGT2378) 是葡萄糖神经酰胺合成酶 (GCS) 和非溶酶体葡萄糖神经酰胺酶 (GBA2) 的双重抑制剂。Sinbaglustat 是一种可透过血脑屏障的的口服N-烷基亚氨基糖。Sinbaglustat 可用于治疗溶酶体贮积症和研究溶酶体功能障碍相关的中枢神经退行性疾病。 | |||
T37456 |
C18 L-erythro Ceramide (d18:1/18:0)
C18 L-erythro Ceramide (d18:1/18:0) |
||
C18 L-erythro Ceramide is a naturally occurring ceramide and stereoisomer of C18 ceramide . It inhibits rat brain mitochondrial ceramidase (mt-CDase) with an IC50 value of 0.11 mol% (8.8 μM). | |||
T37056 |
D-erythro-MAPP
|
||
D-erythro-MAPP is a derivative of ceramide and an inhibitor of alkaline ceramidase (Ki = 2-13 μM; IC50 = 1-5 μM). It is selective for alkaline ceramidase over acid ceramidase (IC50 = >500 μM) as well as the serine/threonine protein phosphatase CAPP at concentrations up to 10 μM. D-erythro-MAPP increases intracellular ceramide levels, induces cell cycle arrest at the G0/G1 phase, and inhibits growth of HL-60 promyelocytic leukemia cells in a time- and concentration-dependent manner. | |||
T69361 |
C16-Urea-Ceramide
|
||
C16-Urea-Ceramide s a neutral ceramidase (nCDase) inhibitor. It is a bioactive ceramide. | |||
T36468 |
ARN14988
|
||
ARN14988 is a potent inhibitor of acid ceramidase (IC50 = 12.8 nM for the human enzyme). It inhibits acid ceramidase activity and increases levels of C16 dihydro ceramide and C16 ceramide in A375, G361, M14, MeWo, MNT-1, and SK-MEL-28 melanoma cells. ARN14988 also reduces growth of A375 and G361 melanoma cells (EC50s = 41.8 and 67.7 μM, respectively). | |||
T11835L |
LCL521 dihydrochloride
1,3DMG-B13 dihydrochloride |
Others | Others |
LCL521 dihydrochloride is a compound that functions as an inhibitor of both acid ceramidase (ACDase) and lysosomal acid sphingomyelinase (ASMase). | |||
T22069 |
D-NMAPPD
|
||
D-NMAPPD ((1R,2R)-B13) 是一种酸性神经酰胺酶 (acid ceramidase) 抑制剂。D-NMAPPD 通过增强神经酰胺的内源性产生来调节 NMDA 受体特性。D-NMAPPD 具有肠癌治疗的潜力。 | |||
T68441 |
SABRAC
|
||
SABRAC inhibits acid ceramidase in PC3 MC metastatic prostate cancer cells (IC50 = <1 µM), as well as induces accumulation of ceramides in the same cells. | |||
T37455 |
C18 D-threo Ceramide (d18:1/18:0)
C18 D-threo Ceramide (d18:1/18:0) |
||
C18 D-threoCeramide (d18:1/18:0) is a synthetic ceramide and stereoisomer of C18 ceramide .1It inhibits rat brain mitochondrial ceramidase (mt-CDase) with an IC50value of 16.6 μM.2[Matreya, LLC. Catalog No. 1855] 1.Koolath, S., Murai, Y., Suga, Y., et al.Chiral combinatorial preparation and biological evaluation of unique ceramides for inhibition of sphingomyelin synthaseChirality32(3)308-313(2019) 2.Usta, J., El Bawab, S., Roddy, P., et al.Structural requirements of ceramide and sphingosine bas... | |||
T82800 |
C12-NBD-ceramide
|
||
C12-NBD-ceramide,一种荧光标记的神经酰胺类似物,常用作神经酰胺酶实验的底物。 | |||
T11835 |
LCL521
|
Others; Phospholipase | Metabolism; Others |
LCL521 能抑制溶酶体酸性鞘磷脂酶(ASMase)。LCL521 是一种酸性神经酰胺酶(ACDase)抑制剂。 | |||
T37457 |
C18 L-threo Ceramide (d18:1/18:0)
C18 L-threo Ceramide (d18:1/18:0) |
||
C18 L-threo Ceramide is a synthetic ceramide and stereoisomer of C18 ceramide that has been used for structural characterization of natural sphingolipids. It inhibits rat brain mitochondrial ceramidase (mt-CDase) with an IC50 value of 0.21 mol% (16.8 μM). | |||
T36321 |
C6 Urea Ceramide
|
||
C6 urea ceramide is an inhibitor of neutral ceramidase.1 It increases total ceramide levels in wild-type mouse embryonic fibroblasts (MEFs) and in HT-29 colon cancer cells but not in MEFs lacking neutral ceramidase. It inhibits proliferation of, and induces apoptosis and autophagy in HT-29, but not non-cancerous RIE-1, cells when used at concentrations of 5 and 10 μM. C6 urea ceramide decreases total β-catenin, increases phosphorylated β-catenin, and induces colocalization of β-catenin with the ... |